162 related articles for article (PubMed ID: 20442311)
1. Preclinical evaluation of nilotinib efficacy in an imatinib-resistant KIT-driven tumor model.
Cullinane C; Natoli A; Hui Y; Conus N; Jackson S; Brüggen J; Manley PW; McArthur GA
Mol Cancer Ther; 2010 May; 9(5):1461-8. PubMed ID: 20442311
[TBL] [Abstract][Full Text] [Related]
2. An in vivo tumor model exploiting metabolic response as a biomarker for targeted drug development.
Cullinane C; Dorow DS; Kansara M; Conus N; Binns D; Hicks RJ; Ashman LK; McArthur GA; Thomas DM
Cancer Res; 2005 Nov; 65(21):9633-6. PubMed ID: 16266981
[TBL] [Abstract][Full Text] [Related]
3. Resistance to c-KIT kinase inhibitors conferred by V654A mutation.
Roberts KG; Odell AF; Byrnes EM; Baleato RM; Griffith R; Lyons AB; Ashman LK
Mol Cancer Ther; 2007 Mar; 6(3):1159-66. PubMed ID: 17363509
[TBL] [Abstract][Full Text] [Related]
4. Juxtamembrane mutant V560GKit is more sensitive to Imatinib (STI571) compared with wild-type c-kit whereas the kinase domain mutant D816VKit is resistant.
Frost MJ; Ferrao PT; Hughes TP; Ashman LK
Mol Cancer Ther; 2002 Oct; 1(12):1115-24. PubMed ID: 12481435
[TBL] [Abstract][Full Text] [Related]
5. Sorafenib inhibits the imatinib-resistant KITT670I gatekeeper mutation in gastrointestinal stromal tumor.
Guo T; Agaram NP; Wong GC; Hom G; D'Adamo D; Maki RG; Schwartz GK; Veach D; Clarkson BD; Singer S; DeMatteo RP; Besmer P; Antonescu CR
Clin Cancer Res; 2007 Aug; 13(16):4874-81. PubMed ID: 17699867
[TBL] [Abstract][Full Text] [Related]
6. The antitumor activity of homoharringtonine against human mast cells harboring the KIT D816V mutation.
Jin Y; Lu Z; Cao K; Zhu Y; Chen Q; Zhu F; Qian C; Pan J
Mol Cancer Ther; 2010 Jan; 9(1):211-23. PubMed ID: 20053766
[TBL] [Abstract][Full Text] [Related]
7. Preclinical evaluation of KIT/PDGFRA and mTOR inhibitors in gastrointestinal stromal tumors using small animal FDG PET.
Pantaleo MA; Nicoletti G; Nanni C; Gnocchi C; Landuzzi L; Quarta C; Boschi S; Nannini M; Di Battista M; Castellucci P; Fanti S; Lollini PL; Bellan E; Castelli M; Rubello D; Biasco G
J Exp Clin Cancer Res; 2010 Dec; 29(1):173. PubMed ID: 21192792
[TBL] [Abstract][Full Text] [Related]
8. Efficacy of the kinase inhibitor SU11248 against gastrointestinal stromal tumor mutants refractory to imatinib mesylate.
Prenen H; Cools J; Mentens N; Folens C; Sciot R; Schöffski P; Van Oosterom A; Marynen P; Debiec-Rychter M
Clin Cancer Res; 2006 Apr; 12(8):2622-7. PubMed ID: 16638875
[TBL] [Abstract][Full Text] [Related]
9. Expression of c-kit receptor in human cholangiocarcinoma and in vivo treatment with imatinib mesilate in chimeric mice.
Kamenz T; Caca K; Blüthner T; Tannapfel A; Mössner J; Wiedmann M
World J Gastroenterol; 2006 Mar; 12(10):1583-90. PubMed ID: 16570351
[TBL] [Abstract][Full Text] [Related]
10. Secondary c-Kit mutations confer acquired resistance to RTK inhibitors in c-Kit mutant melanoma cells.
Todd JR; Becker TM; Kefford RF; Rizos H
Pigment Cell Melanoma Res; 2013 Jul; 26(4):518-26. PubMed ID: 23582185
[TBL] [Abstract][Full Text] [Related]
11. ACRIN 6665/RTOG 0132 phase II trial of neoadjuvant imatinib mesylate for operable malignant gastrointestinal stromal tumor: monitoring with 18F-FDG PET and correlation with genotype and GLUT4 expression.
Van den Abbeele AD; Gatsonis C; de Vries DJ; Melenevsky Y; Szot-Barnes A; Yap JT; Godwin AK; Rink L; Huang M; Blevins M; Sicks J; Eisenberg B; Siegel BA
J Nucl Med; 2012 Apr; 53(4):567-74. PubMed ID: 22381410
[TBL] [Abstract][Full Text] [Related]
12. Mechanisms of resistance to imatinib mesylate in gastrointestinal stromal tumors and activity of the PKC412 inhibitor against imatinib-resistant mutants.
Debiec-Rychter M; Cools J; Dumez H; Sciot R; Stul M; Mentens N; Vranckx H; Wasag B; Prenen H; Roesel J; Hagemeijer A; Van Oosterom A; Marynen P
Gastroenterology; 2005 Feb; 128(2):270-9. PubMed ID: 15685537
[TBL] [Abstract][Full Text] [Related]
13. Intermittent and continuous imatinib in a human GIST xenograft model carrying KIT exon 17 resistance mutation D816H.
Revheim ME; Kristian A; Malinen E; Bruland ØS; Berner JM; Holm R; Joensuu H; Seierstad T
Acta Oncol; 2013 May; 52(4):776-82. PubMed ID: 23480638
[TBL] [Abstract][Full Text] [Related]
14. Phase 2 study of nilotinib as third-line therapy for patients with gastrointestinal stromal tumor.
Sawaki A; Nishida T; Doi T; Yamada Y; Komatsu Y; Kanda T; Kakeji Y; Onozawa Y; Yamasaki M; Ohtsu A
Cancer; 2011 Oct; 117(20):4633-41. PubMed ID: 21456006
[TBL] [Abstract][Full Text] [Related]
15. Selecting tyrosine kinase inhibitors for gastrointestinal stromal tumor with secondary KIT activation-loop domain mutations.
Hsueh YS; Lin CL; Chiang NJ; Yen CC; Li CF; Shan YS; Ko CH; Shih NY; Wang LM; Chen TS; Chen LT
PLoS One; 2013; 8(6):e65762. PubMed ID: 23840364
[TBL] [Abstract][Full Text] [Related]
16. A new mutation in the KIT ATP pocket causes acquired resistance to imatinib in a gastrointestinal stromal tumor patient.
Tamborini E; Bonadiman L; Greco A; Albertini V; Negri T; Gronchi A; Bertulli R; Colecchia M; Casali PG; Pierotti MA; Pilotti S
Gastroenterology; 2004 Jul; 127(1):294-9. PubMed ID: 15236194
[TBL] [Abstract][Full Text] [Related]
17. Inhibition of focal adhesion kinase as a potential therapeutic strategy for imatinib-resistant gastrointestinal stromal tumor.
Sakurama K; Noma K; Takaoka M; Tomono Y; Watanabe N; Hatakeyama S; Ohmori O; Hirota S; Motoki T; Shirakawa Y; Yamatsuji T; Haisa M; Matsuoka J; Tanaka N; Naomoto Y
Mol Cancer Ther; 2009 Jan; 8(1):127-34. PubMed ID: 19139121
[TBL] [Abstract][Full Text] [Related]
18. Early prediction of response to sunitinib after imatinib failure by 18F-fluorodeoxyglucose positron emission tomography in patients with gastrointestinal stromal tumor.
Prior JO; Montemurro M; Orcurto MV; Michielin O; Luthi F; Benhattar J; Guillou L; Elsig V; Stupp R; Delaloye AB; Leyvraz S
J Clin Oncol; 2009 Jan; 27(3):439-45. PubMed ID: 19064982
[TBL] [Abstract][Full Text] [Related]
19. Identification of novel target genes of nerve growth factor (NGF) in human mastocytoma cell line (HMC-1 (V560G c-Kit)) by transcriptome analysis.
Dutta P; Koch A; Breyer B; Schneider H; Dittrich-Breiholz O; Kracht M; Tamura T
BMC Genomics; 2011 Apr; 12():196. PubMed ID: 21501463
[TBL] [Abstract][Full Text] [Related]
20. The HSP90 inhibitor, AT13387, is effective against imatinib-sensitive and -resistant gastrointestinal stromal tumor models.
Smyth T; Van Looy T; Curry JE; Rodriguez-Lopez AM; Wozniak A; Zhu M; Donsky R; Morgan JG; Mayeda M; Fletcher JA; Schöffski P; Lyons J; Thompson NT; Wallis NG
Mol Cancer Ther; 2012 Aug; 11(8):1799-808. PubMed ID: 22714264
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]